Skip to content

Neurocrine Biosciences NBIX Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$668.6M+39.7%$478.6M+11.8%$428M+22.9%$348.3M+13.9%$305.8M-10.4%
$26.6M+2.3%$26M+0.8%$25.8M+4.5%$24.7M-0.4%$24.8M+5.5%
$222.3M+2.0%$217.9M-3.5%$225.7M+5.7%$213.5M+4.8%$203.8M+4.2%
$863.7M+10.3%$782.7M+22.9%$636.8M+12.3%$567.3M+7.1%$529.9M-11.0%
$34.8M-4.4%$36.4M-16.7%$43.7M+13.2%$38.6M+2.4%$37.7M-1.3%
-$784.8M-197%-$264.4M+5.5%-$279.8M
$467.7M+3.9%$450M+50.0%
-$411.2M+41.3%-$700.9M-36.6%
$72.4M-84.9%$480M+5,493%-$8.9M-107%$124.3M+161%-$202.2M-1,017%
$831.3M+11.0%$748.7M+26.2%$593.1M+12.2%$528.7M+7.4%$492.2M-11.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Neurocrine Biosciences generate?
Neurocrine Biosciences (NBIX) generated $863.7M in operating cash flow over the trailing twelve months.
What is Neurocrine Biosciences's free cash flow?
After $34.8M of capital expenditures, Neurocrine Biosciences's free cash flow was $831.3M over the trailing twelve months, up 68.9% year over year.
Where does Neurocrine Biosciences's cash flow data come from?
Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.